Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.

View in: PubMed

subject areas

Aged
Anemia
Case-Control Studies
Darbepoetin alfa
Diabetes Mellitus, Type 2
Erythropoietin
Female
Follow-Up Studies
Hematinics
Humans
Incidence
Logistic Models
Male
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Prospective Studies
Renal Insufficiency, Chronic
Risk Factors
Risk Reduction Behavior
Stroke
Treatment Outcome

authors with profiles

Ajaypal Singh